Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. is seeking shareholder approval of an Option Exchange to replace underwater employee stock options with fewer, longer‑vesting replacement options intended to be "value for value," anti‑dilutive and retention‑focused. Eligible options must be >1 year old with exercise prices ≥$80.00; Executive Committee members, directors and advisors are excluded. The company says 90.8% of eligible employee options were underwater at a $25.10 share price on Aug 27, 2025. If fully subscribed, the program would reduce option overhang by 11.1% and fully diluted share count by 0.8%, and would surrender 3,437,793 options not returned to the equity pool. Moderna disclosed approximately $354M total non‑cash compensation expense related to eligible underwater options, of which $247M is already expensed and $107M remains to be expensed as of Sep 30, 2025. The new replacement options keep the original expiration dates, have a weighted average remaining life of 7.58 years, and will carry additional vesting (one to two years) to promote retention while the company seeks cash‑breakeven by 2028.
Shannon Thyme Klinger, Moderna Chief Legal Officer, reported insider transactions on Form 4 showing restricted stock units converted and shares withheld for taxes. On 08/29/2025, 232 restricted stock units vested and converted one-for-one into 232 shares of Moderna common stock. The reporting person elected to withhold 113 shares to satisfy tax-withholding obligations at a price of $24.47 per share. After these transactions, the reporting person beneficially owned 28,170 shares of common stock. The form is signed by an attorney-in-fact on 09/02/2025. The filing discloses the original vesting schedule: 25% vested on March 1, 2023, with the remainder vesting in twelve equal quarterly installments.
Stephen Hoge, President of Moderna, Inc. (MRNA), reported transactions on Form 4 showing conversion and vesting of restricted stock units (RSUs) on 08/29/2025. A total of 651 RSUs converted into 651 shares of common stock and are reported as acquired; following the transactions he beneficially owns 1,453,512 shares directly and 156,049 shares indirectly (4,116 via Valhalla, LLC and 151,933 via a trust for his spouse and children). Additionally, 315 shares were withheld to satisfy tax withholding obligations related to vesting. The filing is signed by an attorney-in-fact on 09/02/2025.
Insider transactions by Moderna CFO James M. Mock: The filing reports restricted stock unit (RSU) activity for James M. Mock on 08/27/2025 and 08/28/2025. On 08/27/2025, 774 RSUs were converted into 774 shares of common stock and 375 shares were withheld to satisfy tax withholding, leaving 17,340 shares beneficially owned after the reported sale or disposition. On 08/28/2025, 329 RSUs converted into 329 shares and 160 shares were withheld for taxes, leaving 17,509 shares beneficially owned. Vesting schedules for the awards are disclosed and tax-withholding elections are noted.
Reporting person: Shannon Thyme Klinger, Chief Legal Officer of Moderna, reported equity transactions in the issuer's common stock. The filing shows conversion of restricted stock units (RSUs) into common shares and contemporaneous share withholdings to satisfy tax obligations. Specifically, 774 RSUs converted into 774 shares on 08/27/2025 and 329 RSUs converted into 329 shares on 08/28/2025. On 08/27/2025 the reporting person had 28,257 shares after a 774-share conversion and a 375-share withholding; on 08/28/2025 the filing shows 28,051 shares after a 329-share conversion and a 160-share withholding. The RSU awards vest 25% at the initial vesting date with the remainder in twelve equal quarterly installments.
Stephen Hoge, President and director of Moderna, Inc. (MRNA), reported Section 16 transactions showing conversion of restricted stock units into common stock and related share withholding for taxes. On 08/27/2025, 1,437 RSUs converted into common stock and 695 shares were withheld at $24.73 to satisfy tax obligations, leaving 1,453,556 shares beneficially owned after that transaction. On 08/28/2025, 611 RSUs converted and 296 shares were withheld at $25.10, with total owned shares reported at 1,453,176. The report also discloses 4,116 shares held indirectly by Valhalla, LLC and 151,933 shares owned by a trust for the benefit of the reporting person’s spouse and children, of which the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Filing: Form 4 filed for Moderna, Inc. (MRNA) reporting the vesting and conversion of restricted stock units into common stock by Director David M. Rubenstein.
Key facts: On 08/05/2025 850 restricted stock units vested and converted one-for-one into 850 shares of common stock at a price of $0. Following the transaction, the reporting person beneficially owned 1,527 shares. The Form 4 was signed by attorney-in-fact James Dillon on 08/06/2025. The filing indicates a direct ownership form and uses transaction code M with no other transactions disclosed.